What type of study is this?

December 8, 2025Blood

De novo secondary central nervous system lymphoma: A real-world cohort study over two decades

View Full Paper

Ask AI

Bookmark

Authors

Real-world cohort study shows 22.4 years median overall survival in B-cell lymphoma, suggesting favorable outcomes in de novo secondary CNS lymphoma.

Median overall survival reached 22.4 years, demonstrating a positive prognosis for de novo SCNSL patients.
CNS-targeting treatment included intrathecal and intravenous methotrexate, however, no significant differences in outcomes were noted.
Observational analysis of 66 SCNSL patients over two decades highlights systemic treatment regimens such as CHOP and Hyper-CVAD.
Findings suggest a need for further investigation into optimal CNS-targeting regimens for this patient population.

Poon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Real-world cohort study shows 22.4 years median overall survival in B-cell lymphoma, suggesting favorable outcomes in de novo secondary CNS lymphoma.